

SPONSORSHIP AGREEMENT



Parties to this agreement:

Danish Diabetes Association (Diabetesforening)

Stationsparken 24, st tv
2600 Glostrup
CVR DK-35231528

("Recipient")

Novo Nordisk Denmark A/S

Att.: Christian Klyver Tikkanen
Kay Fiskers Plads 10, 7 floor
2300 København S
CVR No. 38180045

("Novo Nordisk")

1. Summary

- 1.1 Recipient's request for support.** The appendix titled "Recipient's request for support" details the specifics of the Recipient's activity(ies) ("the Activity") supported by the sponsorship and purpose of the Activity.

Title of Activity	Health policy opening debate at parliament (Sundhedspolitisk åbningsdebat på Christiansborg) on 1 October 2025
The Sponsorship	<p>Novo Nordisk will provide 96.000 dkk including added tax if applicable to support the Recipient's request.</p> <p>Novo Nordisk will not make any non-financial transfers of value.</p> <p>In exchange for the sponsorship, the Recipient shall provide to Novo Nordisk the tangible benefit of: Delegate passes as well as accreditation of sponsorship during and after the debate.</p> <p>Novo Nordisk is the one of several sponsors of the activity</p>
Agreement Duration	This agreement starts on 01 July 2025 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient's Duties

- 2.1 Compliance with law and ethics.** The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.
- 2.2 Carry out the Activity with proper conduct.** The Recipient shall carry out the Activity independently and in compliance with Novo Nordisk standards and industry codes, in Denmark called ENLI (Etisk nævn for lægemiddelsindustrien).

No use of funds for entertainment	Do not use the sponsorship for leisure or social activities
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment and awards	If sponsorship is used for awards or other payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients
Reasonable choice of venue	Hold activities in a location suitable for the Activity with modest hospitality
Reasonable travel	If sponsorship is used for Activity-related travel, carry out within reasonable time and cost.

Sponsorship Agreement, DK, 2022-DEC

Local Adaptation of HQ Sponsorship Agreement v2

July 2021

Acknowledgment of obligations towards ENLI	<p>Novo Nordisk will only accept support to compensation of mileage to Health Care Professionals that follows ENLI's (Etisk Nævn for Lægemiddelindustrien) tariffs, ref. to §13, 7 in ENLI's Promotion Code. Support that goes towards compensation of car mileage as according to the state tariffs is not permitted.</p> <p>The Recipient acknowledges that Novo Nordisk must report the sponsorship to ENLI (Etisk Nævn for Lægemiddelindustrien) in accordance with ENLI's Patient Organisation Code.</p>
Acknowledgement of obligations towards Danish Medicines Agency	<p>If Danish doctors, nurses, midwives, dentists or pharmacists are affiliated with the activity and receive honorarium from the support provided by Novo Nordisk these persons must be informed about their obligation to report this affiliation to Danish Medicines Agency.</p> <p>The Recipient undertakes to fulfil this information duty and to give Novo Nordisk the following information: Name, authorisation ID, workplace, home address, affiliation start date, affiliation end date. Novo Nordisk must also report this information to the Danish Medicines Agency.</p>

2.3 Physical items provided as-is. If Novo Nordisk donates physical items, the Recipient is solely responsible for the use of such items, and shall assure proper handling and storage of sponsored items after delivery. Novo Nordisk is not liable for the Recipient's use of sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides such items as-is and without any representation or warranty of quality or performance.

2.4 Internal approvals. The Recipient shall obtain all necessary approvals related to the receipt of the sponsorship.

2.5 Inform Novo Nordisk of changes. The Recipient shall inform Novo Nordisk of any changes affecting the request for support. If Novo Nordisk determines the change affects its compliance requirements, Novo Nordisk may demand full or partial return of sponsorship, at the discretion of Novo Nordisk. In the case of return, the Recipient shall comply within 14 days.

2.6 Provide documentation within 1 month. The Recipient shall provide Novo Nordisk with documentation that the sponsorship was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

2.7 Disclose Novo Nordisk as sponsorship provider. The Recipient shall mention Novo Nordisk as the provider of the sponsorship in any public communications or advertising related to the Activity.

2.8 Do not use Novo Nordisk branding without approval. The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

2.9 Allow Novo Nordisk to use Recipient's logo. The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's sponsorship.

2.10

3. Requirements for Financial Sponsorships

3.1 Payment after receipt of invoice. Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Sponsorship amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient

Christian Klyver Tikkanen

3.2 Refund unspent amounts. The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

4. Other Terms and Conditions

4.1 Require Public disclosures. The Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

4.2 No incentive to prescribe or recommend. The sponsorship made by Novo Nordisk indicates no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.

4.3 No conflict of interest. Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship and shall promptly inform Novo Nordisk if such conflict of interest is discovered.

4.4 Compliance hotline. The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com/report-suspected-misconduct).

4.5 Termination for breach. Either party may terminate this contract immediately upon material breach by the other party.

4.6 Governing Law and Dispute Resolution. The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Attachments:

The following attachments are part of this agreement:

Attachment A: Recipient's request for support (application form, letter or email), with timeline and budget

Attachment B: Sponsorships to Health Care Organizations and Patient Organizations: required public disclosures and handling of employee data

6. Agreed to and Accepted by:

Date: 25-Jun-2025 | 3:16 AM PDT

Date: 18-Jun-2025 | 12:39 PM CEST

On behalf of Recipient:

Signed by:

Tanja Thybo

On behalf of Novo Nordisk:

Signed by:

Christian Klyver Tikkanen

Name: Tanja Thybo

Signer Name: Tanja Thybo

Signing Reason: I am authorized to sign on behalf of the recipient

Signing Time: 18-Jun-2025 | 3:47 AM PDT

Title: Head of Research Danish Diabetes Association

Name: Christian Klyver Tikkanen

Signer Name: Christian Klyver Tikkanen

Signing Reason: I have reviewed this document

Signing Time: 18-Jun-2025 | 11:25 AM CEST

Title: Head of Market Access and Rare Disease, Novo Nordisk

Denmark A/S

Date: 25-jun-2025 | 12:29 PM CEST

On behalf of Recipient:

Signed by:

Claus Richter

Name: Claus Richter

Signer Name: Claus Richter

Signing Reason: Jeg godkender dette dokument

Signing Time: 25-jun-2025 | 12:28 PM CEST

Title: CEO Danish Diabetes Association

21B32353305441AF9602A45ECC73F2C6

Attachment A: Recipient's Request for Support

1. Copy of the Recipient's sponsorship request incl. timeline and budget

3. marts 2025

Novo Nordisk

diabetes
foreningen



Ansøgning om støtte til konference på Christiansborg

Diabetesforeningen gentager igen i år den succesfulde tradition og afholder Sundhedspolitisk Åbningsdebat, der i 2025 løber af stablen for fjerde gang.

Formålet med konferencen er at rammesætte en bredere sundhedspolitisk debat. Temaet vil i år være implementeringen af den nye sundhedsreform. Reformen giver et solidt grundlag for at løse de udfordringer med kvalitet og sammenhæng, som patienterne - bl.a. de 365.000 danskere med diabetes - møder i dag. Implementeringen af reformen bliver dog afgørende for, om den kommer til at skabe mærkbare forbedringer for patienterne. På konferencen kommer vi derfor til at stille skarpt på, hvordan vi kommer bedst i mål med at indfri intentionerne bag aftalen, og skabe en bedre fremtid med kronisk sygdom.

Konferencen vil lægge scene til politikere fra hhv. Christiansborg, kommuner og regioner samt eksperter og andre organisationer, der kan perspektivere og debattere temaet.

Konferencen vil løbe af stablen den 1.oktober 2025 og Lea Wermelin, sundhedsordfører for Socialdemokratiet, vil være vært for arrangementet, der afholdes på Christiansborg.

Periode: 1. oktober 2025

Samlet projektbudget: 235.000 kr. eks. moms.

Anmodning om støtte fra Novo Nordisk på 96.000 kr. + moms.

Der søges ligeledes økonomisk støtte hos hhv. Boehringer Ingelheim og Sanofi til Sundhedspolitisk Åbningsdebat.

Den finansielle støtte skal bruges til at dække en del af Diabetesforeningens udgifter i forbindelse med konferencen samt udgifter til delvis moms (Diabetesforeningen har kun mulighed for at trække 19,2 % af momsdelen fra vores udgifter).

Stationsparken 24, st. tv.
2600 Glostrup

Telefon 66 12 90 06
Fax 65 91 49 08
info@diabetes.dk
www.diabetes.dk

CVR-nr. DK-35 23 15 28

Budget:

Udgift	Estimeret pris (ekskl. Moms)
Moderator	35.000 kr.
Transport og honorarer til enkelte oplægsholdere	20.000 kr.
Trykomkostninger	25.000 kr.
Udgifter til moms	16.000 kr.
I alt	96.000 kr.

Appendix B

Transfer of Value Disclosure Appendix

Sponsorship Agreement, DK, 2022-DEC
Local Adaptation of HQ Sponsorship Agreement v2
July 2021

WHY DO WE NEED TO COLLECT AND DISCLOSE YOUR INFORMATION?

Novo Nordisk will collect your data and when required by law, disclose transfer of value provided to Healthcare professionals (“HCPs”) and Healthcare Organizations (“HCOs”) and Patient Organizations (“POs”).

YOUR INFORMATION - WHAT WE COLLECT FOR DISCLOSURE PURPOSES

We collect your personal information (as defined in the list below) to comply with the applicable transparency requirements. This means that we will collect, and may disclose the following information:

Name

Address

Contact details

Nature of relationship with Novo Nordisk

Tax number or unique identifier

Any transfers of value and its payment details from us to you

WHAT ARE YOUR OBLIGATIONS?

If you share personal information about employees of your organisation with us, it is your obligation to inform the employees that their information has been shared with us and that they have been provided the right information as stated in applicable data protection laws including General Data Protection Regulation. Your organization is responsible for any losses caused to Novo Nordisk if the above obligation is not fulfilled.

Notice of Personal Data Processing.

Novo Nordisk is responsible for any processing of your personal data, as set out in the Notice of Personal Data Processing: <https://www.novonordisk.com/contact-us/external-support/external-commitments.html>. The version in force corresponds to the latest version before this agreement was signed. Follow the link for more information about how your data is collected, used, and protected, including your rights and who to contact with requests or concerns.

Certificate Of Completion

Envelope Id: 14CDE4D3-899A-4338-BB25-D0C8B2FBD267

Status: Completed

Subject: Aftale om støtte til diabetes forening møde på Christiansborg

Source Envelope:

Document Pages: 7

Signatures: 3

Envelope Originator:

Certificate Pages: 5

Initials: 0

Nina Donde

AutoNav: Enabled

Novo Alle 1

Envelopeld Stamping: Enabled

Bagsværd, Hovedstaden 02880

Time Zone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris

ndo@novonordisk.com

IP Address: 147.161.155.111

Record Tracking

Status: Original

Holder: Nina Donde

Location: DocuSign

18-Jun-2025 | 10:27

ndo@novonordisk.com

Signer Events

Signature

Timestamp

Christian Klyver Tikkanen

ctik@novonordisk.com

Novo Nordisk Denmark A/S

Security Level: Email, Account Authentication (Required)

Sent: 18-Jun-2025 | 10:33

Viewed: 18-Jun-2025 | 11:21

Signed: 18-Jun-2025 | 12:39

Signature Adoption: Pre-selected Style

Signature ID:

6086C428-5774-4103-947E-E8DD72CAEED2

Using IP Address: 82.192.190.203

With Signing Authentication via Docusign password

With Signing Reasons (on each tab):

I have reviewed this document

Electronic Record and Signature Disclosure:

Not Offered via Docusign

Tanja Thybo

tth@diabetes.dk

Head of Research

Security Level: Email, Account Authentication (Required)

Sent: 18-Jun-2025 | 12:39

Resent: 24-Jun-2025 | 08:47

Resent: 25-Jun-2025 | 08:47

Viewed: 25-Jun-2025 | 12:16

Signed: 25-Jun-2025 | 12:16

Signature Adoption: Pre-selected Style

Signature ID:

E8906967-3442-43C3-AD89-1B458C940C8D

Using IP Address: 152.115.68.2

With Signing Authentication via Docusign password

With Signing Reasons (on each tab):

I am authorized to sign on behalf of the company

Electronic Record and Signature Disclosure:

Accepted: 18-Jun-2025 | 12:47

ID: 3cdb581d-4c31-483d-bac8-e5d4a87dd6e4

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Claus Richter
cr@diabetes.dk
CEO



Sent: 25-Jun-2025 | 12:16
Viewed: 25-Jun-2025 | 12:28
Signed: 25-Jun-2025 | 12:29

Security Level: Email, Account Authentication (Required)

Signature Adoption: Uploaded Signature Image
Signature ID:
21B32353-3054-41AF-9602-A45ECC73F2C6
Using IP Address: 152.115.68.2

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
Jeg godkender dette dokument

Electronic Record and Signature Disclosure:
Accepted: 25-Jun-2025 | 12:28
ID: 5153eefa-0220-4c86-9ee2-ed061df8acf3

In Person Signer Events	Signature	Timestamp
-------------------------	-----------	-----------

Editor Delivery Events	Status	Timestamp
------------------------	--------	-----------

Agent Delivery Events	Status	Timestamp
-----------------------	--------	-----------

Intermediary Delivery Events	Status	Timestamp
------------------------------	--------	-----------

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	18-Jun-2025 10:33
Certified Delivered	Security Checked	25-Jun-2025 12:28
Signing Complete	Security Checked	25-Jun-2025 12:29
Completed	Security Checked	25-Jun-2025 12:29

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Novo Nordisk A/S (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Novo Nordisk A/S:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: urcm@novonordisk.com

To advise Novo Nordisk A/S of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at urcm@novonordisk.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Novo Nordisk A/S

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to urcm@novonordisk.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Novo Nordisk A/S

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to urcm@novonordisk.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Novo Nordisk A/S as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Novo Nordisk A/S during the course of your relationship with Novo Nordisk A/S.